What Should Be the Rules for Downstaging for Hepatocellular Carcinoma?

Basit Öğe Kaydı
dc.authoridKARAKAS, SERDAR/0000-0001-8314-7806
dc.authorwosidKARAKAS, SERDAR/AAB-3219-2021
dc.contributor.authorDirican, Abuzer
dc.contributor.authorKarakas, Serdar
dc.date.accessioned2024-08-04T20:48:49Z
dc.date.available2024-08-04T20:48:49Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction Liver transplantation remains the main curative treatment method for hepatocellular carcinoma. There are several criteria for hepatocellular carcinoma to be eligible for liver transplantation, and it depends on main transplantation centers worldwide. Locoregional treatments and downstaging protocols are used for either to achieve these criteria or to prevent drop outs on the transplant waiting lists. But who can benefit from these bridging therapies effectively for the main purpose of curative treatment? Main contraindications are known for locoregional treatments like cirrhosis or low hepatic function, total main portal vein occlusion, and extrahepatic metastasis. HCCs, which are confined to liver but have high tumor burden, remains the main controversial issue. Aim On this aspect, we reviewed the literature for downstaging protocols for hepatocellular carcinoma with their effect on survival and recurrence rates after liver transplantation. Conclusion Although candidates for downstaging is still controversial, with the absence of main contraindications, LRT can be applied to selected HCCs, which have a certain degree of tumor burden.en_US
dc.identifier.doi10.1007/s12029-020-00490-0
dc.identifier.endpage1151en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue4en_US
dc.identifier.pmid32839945en_US
dc.identifier.scopus2-s2.0-85089780177en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1148en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-020-00490-0
dc.identifier.urihttps://hdl.handle.net/11616/99478
dc.identifier.volume51en_US
dc.identifier.wosWOS:000562326000002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLiver transplantationen_US
dc.subjectDownstaging protocolen_US
dc.subjectLocoregional treatmenten_US
dc.subjectHepatocellular carcinomaen_US
dc.titleWhat Should Be the Rules for Downstaging for Hepatocellular Carcinoma?en_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu